Coya Therapeutics specializes in enhancing regulatory T cell (Treg) function through innovative combination biologics, primarily COYA 302, currently in Phase 2 trials for ALS with expansion plans into frontotemporal dementia. The company has demonstrated accelerating revenue growth alongside increasing operating losses attributable to intensified R&D investment. Upcoming Phase 2 data readouts represent critical inflection points, while Coya’s exclusive licensing agreements underpin its intellectual property moat and manufacturing strategy. However, clinical, regulatory, and reimbursement risks remain significant challenges given the early-stage nature of its pipeline and ongoing capital requirements.